Expanding Access to Lyophilized Therapies: Reunite removes reliance on vial kits and manual reconstitution, making ...

Both companies have upped their offers for Metsera amid a bidding war, but Novo Nordisk comes armed with an extra $1.9bn.

Ensuring fair drug pricing was a key promise of Sri Lanka’s government’s election manifesto, and that promise is finally ...

ADCs remain à la mode in the oncology sector, with Merck & Co (MSD) tying up another deal to advance its pipeline in the ...

The path to approval for uniQure’s gene therapy candidate for Huntington’s disease is in doubt as the US Food and Drug ...

AmacaThera has entered into an exclusive worldwide licensing agreement with Pacira BioSciences for up to $230m for AMT-143, an investigational long-acting non-opioid anaesthetic.

Boehringer Ingelheim and CDR-Life have announced a worldwide licencing agreement for the development of CDR111, an antibody-based molecule targeting autoimmune conditions.

Their combined market capitalisation rose 4% from $3.7 trillion on 30 June 2025 to $3.8 trillion on 30 September 2025.

US consumer health company Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for ...

Alvotech, with its strategic commercialisation partner Advanz Pharma, received EMA approval for Mynzepli (AVT06) in August ...

The FDA has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat genetic mitochondrial disease, thymidine kinase 2 ...

The resignation of the FDA's head drug regulator George Tidmarsh comes amid concerns about conduct related to lupus nephritis drug Lupkynis.